Distinguished in Nasopharyngeal Carcinoma

Carlo Resteghini

Head And Neck Medical Oncology Unit, 
Milan, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Nasopharyngeal Carcinoma
Head And Neck Medical Oncology Unit, 
Milan, IT 
OverviewLocationsClinical Research

Overview

Carlo Resteghini practices in Milan, Italy. Mr. Resteghini is rated as a Distinguished expert by MediFind in the treatment of Nasopharyngeal Carcinoma. His top areas of expertise are Nasopharyngeal Carcinoma, Adenoid Cystic Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Liver Embolization, and Laryngectomy.

His clinical research consists of co-authoring 69 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Nasopharyngeal Carcinoma.

Gender
Male

Locations

Head And Neck Medical Oncology Unit, Milan, 20133, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multicenter Randomized Trial for Quality of Life Evaluation by Non-invasive Intelligent Tools During Post-curative Treatment Follow-up for Head and Neck Cancer
A Multicenter Randomized Trial for Quality of Life Evaluation by Non-invasive Intelligent Tools During Post-curative Treatment Follow-up for Head and Neck Cancer
Enrollment Status: Recruiting
Publish Date: February 02, 2024
Intervention Type: Other
Study Phase: Not Applicable
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
Enrollment Status: Completed
Publish Date: September 03, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract
Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract
Enrollment Status: Completed
Publish Date: August 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
Enrollment Status: Unknown
Publish Date: September 05, 2017
Intervention Type: Drug, Radiation
Study Drugs: Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab
Study Phase: Phase 3
View 3 Less Clinical Trials

69 Total Publications

The interplay of hypoxia, inflammation, and microbiota as indicators of malignant transformation in oral potentially malignant disorders.
The interplay of hypoxia, inflammation, and microbiota as indicators of malignant transformation in oral potentially malignant disorders.
Journal: Oral oncology
Published: May 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Resteghini's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile